|
nasdaq:ormp
|
365036
|
Apr 14th, 2024 12:00AM
|
Oramed Pharmaceuticals Inc.
|
3.3K
|
15.00
|
Open
|
|
Apr 13th, 2024 11:30PM
|
Apr 13th, 2024 11:30PM
|
Oramed Pharmaceuticals (NASDAQ:ORMP) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection.
Through its patented flagship product, an orally ingestible insulin capsule currently in Phase 3 trials under the USFDA, the Company is seeking to revolutionize the treatment of diabetes.
Read more: http://www.oramed.com/investors/corporate-presentation
Watch: https://www.youtube.com/watch?v=5qChxTDV9eg
Terms and conditions and privacy policy: https://www.oramed.com/web-site-terms-and-conditions/
|
Open
|
Oral insulin, Pharmaceuticals, GLP-1, Diabetes, Diabetes Type 1, Diabetes Type 2, Insulin, Insulin Research, Diabetes Research, and biotech
|
Open
|
20 Mamilla Avenue
|
Jerusalem
|
|
IL
|
9414904
|
|
Oramed Pharmaceuticals
|
|
Health Care Equipment & Services
|
|
nasdaq:ormp
|
365036
|
Apr 13th, 2024 12:00AM
|
Oramed Pharmaceuticals Inc.
|
3.3K
|
15.00
|
Open
|
|
Apr 12th, 2024 11:21PM
|
Apr 13th, 2024 11:55AM
|
Oramed Pharmaceuticals (NASDAQ:ORMP) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection.
Through its patented flagship product, an orally ingestible insulin capsule currently in Phase 3 trials under the USFDA, the Company is seeking to revolutionize the treatment of diabetes.
Read more: http://www.oramed.com/investors/corporate-presentation
Watch: https://www.youtube.com/watch?v=5qChxTDV9eg
Terms and conditions and privacy policy: https://www.oramed.com/web-site-terms-and-conditions/
|
Open
|
Oral insulin, Pharmaceuticals, GLP-1, Diabetes, Diabetes Type 1, Diabetes Type 2, Insulin, Insulin Research, Diabetes Research, and biotech
|
Open
|
20 Mamilla Avenue
|
Jerusalem
|
|
IL
|
9414904
|
|
Oramed Pharmaceuticals
|
|
Health Care Equipment & Services
|
|
nasdaq:ormp
|
365036
|
Apr 12th, 2024 12:00AM
|
Oramed Pharmaceuticals Inc.
|
3.3K
|
15.00
|
Open
|
|
Apr 11th, 2024 11:27PM
|
Apr 12th, 2024 08:50AM
|
Oramed Pharmaceuticals (NASDAQ:ORMP) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection.
Through its patented flagship product, an orally ingestible insulin capsule currently in Phase 3 trials under the USFDA, the Company is seeking to revolutionize the treatment of diabetes.
Read more: http://www.oramed.com/investors/corporate-presentation
Watch: https://www.youtube.com/watch?v=5qChxTDV9eg
Terms and conditions and privacy policy: https://www.oramed.com/web-site-terms-and-conditions/
|
Open
|
Oral insulin, Pharmaceuticals, GLP-1, Diabetes, Diabetes Type 1, Diabetes Type 2, Insulin, Insulin Research, Diabetes Research, and biotech
|
Open
|
20 Mamilla Avenue
|
Jerusalem
|
|
IL
|
9414904
|
|
Oramed Pharmaceuticals
|
|
Health Care Equipment & Services
|
|
nasdaq:ormp
|
365036
|
Apr 11th, 2024 12:00AM
|
Oramed Pharmaceuticals Inc.
|
3.3K
|
15.00
|
Open
|
|
Apr 10th, 2024 11:59PM
|
Apr 11th, 2024 11:36AM
|
Oramed Pharmaceuticals (NASDAQ:ORMP) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection.
Through its patented flagship product, an orally ingestible insulin capsule currently in Phase 3 trials under the USFDA, the Company is seeking to revolutionize the treatment of diabetes.
Read more: http://www.oramed.com/investors/corporate-presentation
Watch: https://www.youtube.com/watch?v=5qChxTDV9eg
Terms and conditions and privacy policy: https://www.oramed.com/web-site-terms-and-conditions/
|
Open
|
Oral insulin, Pharmaceuticals, GLP-1, Diabetes, Diabetes Type 1, Diabetes Type 2, Insulin, Insulin Research, Diabetes Research, and biotech
|
Open
|
20 Mamilla Avenue
|
Jerusalem
|
|
IL
|
9414904
|
|
Oramed Pharmaceuticals
|
|
Health Care Equipment & Services
|
|
nasdaq:ormp
|
365036
|
Apr 10th, 2024 12:00AM
|
Oramed Pharmaceuticals Inc.
|
3.3K
|
15.00
|
Open
|
|
Apr 9th, 2024 11:29PM
|
Apr 10th, 2024 05:43PM
|
Oramed Pharmaceuticals (NASDAQ:ORMP) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection.
Through its patented flagship product, an orally ingestible insulin capsule currently in Phase 3 trials under the USFDA, the Company is seeking to revolutionize the treatment of diabetes.
Read more: http://www.oramed.com/investors/corporate-presentation
Watch: https://www.youtube.com/watch?v=5qChxTDV9eg
Terms and conditions and privacy policy: https://www.oramed.com/web-site-terms-and-conditions/
|
Open
|
Oral insulin, Pharmaceuticals, GLP-1, Diabetes, Diabetes Type 1, Diabetes Type 2, Insulin, Insulin Research, Diabetes Research, and biotech
|
Open
|
20 Mamilla Avenue
|
Jerusalem
|
|
IL
|
9414904
|
|
Oramed Pharmaceuticals
|
|
Health Care Equipment & Services
|
|
nasdaq:ormp
|
365036
|
Apr 9th, 2024 12:00AM
|
Oramed Pharmaceuticals Inc.
|
3.3K
|
15.00
|
Open
|
|
Apr 8th, 2024 11:40PM
|
Apr 9th, 2024 10:25AM
|
Oramed Pharmaceuticals (NASDAQ:ORMP) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection.
Through its patented flagship product, an orally ingestible insulin capsule currently in Phase 3 trials under the USFDA, the Company is seeking to revolutionize the treatment of diabetes.
Read more: http://www.oramed.com/investors/corporate-presentation
Watch: https://www.youtube.com/watch?v=5qChxTDV9eg
Terms and conditions and privacy policy: https://www.oramed.com/web-site-terms-and-conditions/
|
Open
|
Oral insulin, Pharmaceuticals, GLP-1, Diabetes, Diabetes Type 1, Diabetes Type 2, Insulin, Insulin Research, Diabetes Research, and biotech
|
Open
|
20 Mamilla Avenue
|
Jerusalem
|
|
IL
|
9414904
|
|
Oramed Pharmaceuticals
|
|
Health Care Equipment & Services
|
|
nasdaq:ormp
|
365036
|
Apr 8th, 2024 12:00AM
|
Oramed Pharmaceuticals Inc.
|
3.3K
|
15.00
|
Open
|
|
Apr 8th, 2024 12:04AM
|
Apr 8th, 2024 07:22PM
|
Oramed Pharmaceuticals (NASDAQ:ORMP) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection.
Through its patented flagship product, an orally ingestible insulin capsule currently in Phase 3 trials under the USFDA, the Company is seeking to revolutionize the treatment of diabetes.
Read more: http://www.oramed.com/investors/corporate-presentation
Watch: https://www.youtube.com/watch?v=5qChxTDV9eg
Terms and conditions and privacy policy: https://www.oramed.com/web-site-terms-and-conditions/
|
Open
|
Oral insulin, Pharmaceuticals, GLP-1, Diabetes, Diabetes Type 1, Diabetes Type 2, Insulin, Insulin Research, Diabetes Research, and biotech
|
Open
|
20 Mamilla Avenue
|
Jerusalem
|
|
IL
|
9414904
|
|
Oramed Pharmaceuticals
|
|
Health Care Equipment & Services
|
|
nasdaq:ormp
|
365036
|
Apr 7th, 2024 12:00AM
|
Oramed Pharmaceuticals Inc.
|
3.3K
|
15.00
|
Open
|
|
Apr 6th, 2024 11:35PM
|
Apr 6th, 2024 11:35PM
|
Oramed Pharmaceuticals (NASDAQ:ORMP) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection.
Through its patented flagship product, an orally ingestible insulin capsule currently in Phase 3 trials under the USFDA, the Company is seeking to revolutionize the treatment of diabetes.
Read more: http://www.oramed.com/investors/corporate-presentation
Watch: https://www.youtube.com/watch?v=5qChxTDV9eg
Terms and conditions and privacy policy: https://www.oramed.com/web-site-terms-and-conditions/
|
Open
|
Oral insulin, Pharmaceuticals, GLP-1, Diabetes, Diabetes Type 1, Diabetes Type 2, Insulin, Insulin Research, Diabetes Research, and biotech
|
Open
|
20 Mamilla Avenue
|
Jerusalem
|
|
IL
|
9414904
|
|
Oramed Pharmaceuticals
|
|
Health Care Equipment & Services
|
|
nasdaq:ormp
|
365036
|
Apr 6th, 2024 12:00AM
|
Oramed Pharmaceuticals Inc.
|
3.3K
|
16.00
|
Open
|
|
Apr 5th, 2024 11:35PM
|
Apr 5th, 2024 11:35PM
|
Oramed Pharmaceuticals (NASDAQ:ORMP) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection.
Through its patented flagship product, an orally ingestible insulin capsule currently in Phase 3 trials under the USFDA, the Company is seeking to revolutionize the treatment of diabetes.
Read more: http://www.oramed.com/investors/corporate-presentation
Watch: https://www.youtube.com/watch?v=5qChxTDV9eg
Terms and conditions and privacy policy: https://www.oramed.com/web-site-terms-and-conditions/
|
Open
|
Oral insulin, Pharmaceuticals, GLP-1, Diabetes, Diabetes Type 1, Diabetes Type 2, Insulin, Insulin Research, Diabetes Research, and biotech
|
Open
|
20 Mamilla Avenue
|
Jerusalem
|
|
IL
|
9414904
|
|
Oramed Pharmaceuticals
|
|
Health Care Equipment & Services
|
|
nasdaq:ormp
|
365036
|
Apr 5th, 2024 12:00AM
|
Oramed Pharmaceuticals Inc.
|
3.3K
|
16.00
|
Open
|
|
Apr 5th, 2024 12:03AM
|
Apr 5th, 2024 12:03AM
|
Oramed Pharmaceuticals (NASDAQ:ORMP) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection.
Through its patented flagship product, an orally ingestible insulin capsule currently in Phase 3 trials under the USFDA, the Company is seeking to revolutionize the treatment of diabetes.
Read more: http://www.oramed.com/investors/corporate-presentation
Watch: https://www.youtube.com/watch?v=5qChxTDV9eg
Terms and conditions and privacy policy: https://www.oramed.com/web-site-terms-and-conditions/
|
Open
|
Oral insulin, Pharmaceuticals, GLP-1, Diabetes, Diabetes Type 1, Diabetes Type 2, Insulin, Insulin Research, Diabetes Research, and biotech
|
Open
|
20 Mamilla Avenue
|
Jerusalem
|
|
IL
|
9414904
|
|
Oramed Pharmaceuticals
|
|
Health Care Equipment & Services
|